About: Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 04 September 2007

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2007 (uk) article scientifique publié en 2007 (fr) im Oktober 2007 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 04 September 2007 (en) artículu científicu espublizáu en setiembre de 2007 (ast)
publication date	wds:Q62392239-642F4174-8432-4CDD-96B5-98ADEACB2DCB
publication date	2007-09-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q62392239-6DAFA57C-D212-43C5-837C-A4CD99709ACA
language of work or name	English
author name string	wds:Q62392239-0A0775A9-67C1-42EF-9025-387235144715 wds:Q62392239-252F92A7-DB24-447A-9A13-E69C22412ADF wds:Q62392239-2B0B30EE-D3DC-4997-B8C3-38A320503C87 wds:Q62392239-577E8218-F749-4859-86F7-F45C6F7CCB74 wds:Q62392239-5B15DB42-1032-4A99-A4AA-06D6BD0E1597 wds:Q62392239-6D124418-50C9-4EF3-BFA5-4885F4C7A3A2 wds:Q62392239-713E2D61-0473-45DC-A98E-6AFA6C5B619D wds:Q62392239-7466F164-F4A0-4F05-A873-F0CC08DE44AC wds:Q62392239-85C5916E-2E19-4A24-AE8D-40D906EE103C wds:Q62392239-901D600A-7B61-4D46-97A5-C69EBC1E96F9 wds:Q62392239-9E919022-902E-4871-8156-427B6516EFE9 wds:Q62392239-E27B0EDE-B733-43BE-92DD-97BE13430768 wds:Q62392239-EB576EE5-062C-4635-B08D-12462BF025C0 wds:Q62392239-EE2A87DA-5A28-4C4B-9A39-F6FCEEFF1095 wds:Q62392239-F4E93BE3-28E3-4455-9374-DD953006FF34
author name string	Robert Coleman Allan Lipton Pere Gascon Jean-Jacques Body Susie Jun Alexander H G Paterson Philippe Solal-Celigny Guenther G Steger Michelle Fan Richard de Boer Amy Kinsey Cristina Alvarado Jazmin Figueroa Katia S Tonkin Mark C Peterson
rdfs:label	Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases (en) Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases (nl)
skos:prefLabel	Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases (en) Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases (nl)
name	Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases (en) Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases (nl)
author	wds:Q62392239-61DD44B1-7442-4662-820F-DB040BD36212
author	Rossana Berardi
title	wds:Q62392239-14376DD8-B53F-427D-A833-150D5EB442CD
title	Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases (en)
page(s)	wds:Q62392239-5D18F1BB-67CB-4930-8CB7-EDB59A81C7AE
page(s)	4431-4437
instance of	wds:Q62392239-FAE923D0-88F8-4D0E-842F-B7A6615D9070
instance of	scholarly article
PubMed ID	wds:Q62392239-389B77FA-6CA8-404B-B505-3567567F17C1
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17785705
PubMed ID	17785705
published in	wds:Q62392239-AD69E785-B4CD-44E1-8E74-AD1FE20B434E
published in	Journal of Clinical Oncology
issue	wds:Q62392239-B95398A8-CBCE-4E16-9A10-A45C5BCE8759
volume	wds:Q62392239-8CE053F4-559D-4377-9EBD-4A5CB9652733
issue	28
volume	25
DOI	wds:Q62392239-5DD26880-9179-4A64-B204-4EE093115D93
DOI	http://dx.doi.org/10.1200/JCO.2007.11.8604
DOI	10.1200/JCO.2007.11.8604
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q62392239
is cites work of	A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Bisphosphonates and other bone agents for breast cancer The best of both worlds - managing the cancer, saving the bone Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis Interaction among cells of bone, immune system, and solid tumors leads to bone metastases Osteonecrosis of the jaw in a patient on Denosumab In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease Bone metastasis: mechanisms and therapeutic opportunities Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. RANKL/RANK-beyond bones An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Rethinking the metastatic cascade as a therapeutic target Mechanisms of bone metastases of breast cancer Colony-stimulating factor 1 potentiates lung cancer bone metastasis Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Targeting bone metastases in prostate cancer: improving clinical outcome Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases RANK, RANKL and osteoprotegerin in bone biology and disease. Role of NF-κB in the skeleton Treatment and prevention of bone complications from prostate cancer The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients Advances in the treatment of breast cancer Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma Future directions of bone-targeted therapy for metastatic breast cancer Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software